Practical guide to the management of osteoporosis in men with prostate cancer receiving androgen-deprivation therapy Jan M. Bruder Invited Commentary Pages: 157 - 158
Targeting osseous metastases: rationale and development of radioimmunotherapy for prostate cancer Michael J. MorrisNeeta Pandit-TaskarHoward I. Scher OriginalPaper Pages: 163 - 170
Biomarkers for the detection and prognosis of prostate cancer Javier HernandezEdith Canby-HaginoIan M. Thompson OriginalPaper Pages: 171 - 176
What’s new in the field of prostate cancer chemoprevention? Kanwaljit MahalJavier HernandezIan M. Thompson OriginalPaper Pages: 177 - 182
Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated? Edith D. Canby-HaginoGregory P. SwansonIan M. Thompson OriginalPaper Pages: 183 - 189
Critical review of the efficacy and safety of cryotherapy of the prostate James Cliftton Vestal OriginalPaper Pages: 190 - 193
The efficacy of conventional external beam, three-dimensional conformal, intensity-modulated, particle beam radiation, and brachytherapy for localized prostate cancer Tony Y. EngJoin Y. LuhCharles R. Thomas OriginalPaper Pages: 194 - 209
Complications of androgen-deprivation therapy in men with prostate cancer Allen C. ChenDaniel P. Petrylak OriginalPaper Pages: 210 - 216
Preventing and treating the complications of hormone therapy Ravi J. KumarAl BarqawiE. David Crawford OriginalPaper Pages: 217 - 223
Chemotherapy agents and timing of chemotherapy in prostate cancer management Kathleen M. DonohueDaniel P. Petrylak OriginalPaper Pages: 224 - 227
Multidisciplinary management of prostate malignancy Joseph W. BaslerCarol JenkinsGregory Swanson OriginalPaper Pages: 228 - 234